Is zolbetuximab available for purchase in China?

Zolbetuximab (zolbetuximab)-Vyloy, as a new type of targeted monoclonal antibody, has been approved for marketing in China. This is undoubtedly an important development for patients with gastric cancer and gastroesophageal junction adenocarcinoma. However, it should be noted that this drug has not yet been included in the national medical insurance catalog, so there is still a certain price burden, and patients need to bear all the costs themselves when purchasing the drug.

According to the data, the domestic channels for obtaining zotuximab mainly rely on regular hospitals and professional pharmacies. In particular, the oncology or pharmacy departments of tertiary A hospitals can usually provide the use of this drug. During the treatment process, if the doctor assesses that the patient is suitable for this treatment plan, he or she can obtain the medicine directly through the in-hospital pharmacy. Because it is an imported original drug and its supply channels are relatively concentrated, there may be certain differences in prices. Patients need to consult their hospital or designated pharmacy for specific costs.

Compared with some new overseas drugs that have not yet been introduced, the fact that zotuximab can be launched in China shows that it has been highly recognized in terms of clinical value and market demand. However, the lack of coverage by medical insurance means that many patients face greater financial pressure when receiving long-term treatment, which is also the focus of future policies and industry. Once zotuximab is successfully included in the medical insurance catalog, its clinical accessibility will be greatly improved, and more patients will be able to enjoy the therapeutic benefits brought by innovative drugs while reducing their financial burden.

In the international market, zotuximab is also in the early stages of promotion and has not yet formed a wide supply of generic drugs. Therefore, patients currently mainly rely on the original version of the drug. For domestic patients, purchasing through formal channels can not only ensure the quality and efficacy of medicines, but also avoid risks caused by gray channels.

Reference materials:https://www.astellas.com/en/news/29401